This small biotech could grow much larger with some good news from its pipeline.

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around for cash to prevent the company from going bust. The Canadian biotech, whose ...

PDS Biotech has released data from the Phase II investigator-led colorectal cancer trial.

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Since then, the stock has delivered market-beating returns thanks to significant clinical and regulatory progress, as well as ...

Two biotech companies have surged on recent developments, illustrating biotech’s volatility and prompting investors to evaluate potential long-term value. The biotechnology sector is inherently ...

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

The latest trial milestone sends this ASX biotech stock higher today. The post This ASX biotech stock just jumped again as ...

Biotech finance teams know the pain: complex models across tabs, manually pulled data and hours validating formulas. Switching between Excel, web sources and chat tools makes even simple runway ...

DAFNA Capital Management sold 222,847 SNDX shares in the fourth quarter for an estimated roughly $4 million. Meanwhile, the quarter-end position value decreased by $1.87 million, reflecting both ...

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication towards being a top contender in the highly contested biotech market. So, ...